OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Profitability
This table compares OnKure Therapeutics and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OnKure Therapeutics | N/A | -51.17% | -47.11% |
| Sol-Gel Technologies | -81.75% | -27.17% | -22.49% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for OnKure Therapeutics and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OnKure Therapeutics | 0 | 0 | 3 | 2 | 3.40 |
| Sol-Gel Technologies | 0 | 0 | 2 | 0 | 3.00 |
Risk & Volatility
OnKure Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
Institutional and Insider Ownership
91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares OnKure Therapeutics and Sol-Gel Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OnKure Therapeutics | N/A | N/A | -$77.39 million | ($6.57) | -0.77 |
| Sol-Gel Technologies | $11.71 million | 1.28 | -$27.24 million | ($0.34) | -1.58 |
Sol-Gel Technologies has higher revenue and earnings than OnKure Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sol-Gel Technologies beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
